NeoStem Subsidiary Receives SFDA Approval for Antibiotic
April 06, 2010 at 00:35 AM EDT
NeoStem, Inc. reported that its China subsidiary, Suzhou Erye Pharma, was granted SFDA approval to produce cloxacillin sodium API, a generic anti-infective. Because it is included in China’s National Medical Reimbursement Insurance List, Cloxacillin sodium is eligible for reimbursement by the government's healthcare programs. More details... Stock Symbol: (NYSE Amex: NBS)